Which returned more over the last year, BSV or XBI?

In the year to Sep 12, 2026, with distributions reinvested, BSV returned +1.1% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.

Which is cheaper, BSV or XBI?

BSV charges 0.03% a year and XBI charges 0.35%, so BSV is cheaper. Fees come from each fund's prospectus.

Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.

ETFIQetfiq.com · independent ETF data

BSV vs XBI: how they differ

BSV and XBI hold 0% of their weight in the same names, and XBI returned more over the year.

Vanguard Short-Term Bond Index Fund and State Street(R) SPDR(R) S&P(R) Biotech ETF.

What they hold in common

By the books each fund has filed, BSV and XBI hold 0% of their money in the same securities at the same weight.

Largest positions each one holds and the other does not
Only in BSV	Only in XBI
United States Treasury Note/Bond 1.13%	Apogee Therapeutics Inc 1.49%
United States Treasury Note/Bond 0.90%	Moderna Inc 1.41%
United States Treasury Note/Bond 0.89%	Twist Bioscience Corp 1.41%
United States Treasury Note/Bond 0.82%	Oruka Therapeutics Inc 1.38%
United States Treasury Note/Bond 0.81%	Kymera Therapeutics Inc 1.36%
United States Treasury Note/Bond 0.81%	Viking Therapeutics Inc 1.31%
United States Treasury Note/Bond 0.80%	Praxis Precision Medicines Inc 1.29%
United States Treasury Note/Bond 0.78%	Erasca Inc 1.27%

Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026.

BSV and XBI on the fields both publish, as of Sep 12, 2026. Source: ETFIQ.
	BSV Vanguard Short-Term Bond Index Fund	XBI State Street(R) SPDR(R) S&P(R) Biotech ETF
Where it sits	Core index fund	Core index fund
Issuer	Vanguard	State Street
What it is	Short-Term Bond	SPDR S&P Biotech
Total return, 1 year	+1.1%	+64.0%
S&P 500 over the same days	+17.5%	+17.5%
Gap to the S&P 500	−16.4 pts	+46.5 pts
Expense ratio	0.03%	0.35%
Holdings	3185	150

BSV in plain words

BSV is a bond fund tracking the Short-Term Bond. Over the year to Sep 11, 2026 it returned +1.1% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.03% a year.

XBI in plain words

XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Jun 30, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 150 positions, with the top ten at 13.3%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.

Questions people ask

Which returned more over the last year, BSV or XBI?: In the year to Sep 12, 2026, with distributions reinvested, BSV returned +1.1% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.
Which is cheaper, BSV or XBI?: BSV charges 0.03% a year and XBI charges 0.35%, so BSV is cheaper. Fees come from each fund's prospectus.

Other comparisons

Where to next

Where these figures came from

ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.

BSV against XBI, ETFIQ, data as of Sep 12, 2026. Every figure is arithmetic on a named public source; the method is at etfiq.com/methodology. A comparison is not a recommendation.

Cite this page. ETFIQ, BSV against XBI, data as of Sep 12, 2026. https://etfiq.com/compare/any/BSV-XBI Free to use with attribution; the underlying files are at Open data.

A comparison is not a recommendation. Standards and sources